GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Return-on-Tangible-Asset

Nova Mentis Life Science (Nova Mentis Life Science) Return-on-Tangible-Asset : -1,211.43% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Nova Mentis Life Science's annualized Net Income for the quarter that ended in Mar. 2024 was $-0.42 Mil. Nova Mentis Life Science's average total tangible assets for the quarter that ended in Mar. 2024 was $0.04 Mil. Therefore, Nova Mentis Life Science's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -1,211.43%.

The historical rank and industry rank for Nova Mentis Life Science's Return-on-Tangible-Asset or its related term are showing as below:

NMLSF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -524   Med: -178.53   Max: -16
Current: -304.64

During the past 13 years, Nova Mentis Life Science's highest Return-on-Tangible-Asset was -16.00%. The lowest was -524.00%. And the median was -178.53%.

NMLSF's Return-on-Tangible-Asset is ranked worse than
94.26% of 1550 companies
in the Biotechnology industry
Industry Median: -40.42 vs NMLSF: -304.64

Nova Mentis Life Science Return-on-Tangible-Asset Historical Data

The historical data trend for Nova Mentis Life Science's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Return-on-Tangible-Asset Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.28 -20.00 -533.99 -136.86 -400.22

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -124.86 -578.15 -800.00 -525.60 -1,211.43

Competitive Comparison of Nova Mentis Life Science's Return-on-Tangible-Asset

For the Biotechnology subindustry, Nova Mentis Life Science's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Return-on-Tangible-Asset falls into.



Nova Mentis Life Science Return-on-Tangible-Asset Calculation

Nova Mentis Life Science's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-1.815/( (0.688+0.219)/ 2 )
=-1.815/0.4535
=-400.22 %

Nova Mentis Life Science's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Sep. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Sep. 2023 )(Q: Mar. 2024 )
=-0.424/( (0.04+0.03)/ 2 )
=-0.424/0.035
=-1,211.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Nova Mentis Life Science  (OTCPK:NMLSF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Nova Mentis Life Science Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

By PRNewswire PRNewswire 11-09-2021

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021